Onyx, Bayer Phase II HCC data

ONXX and partner Bayer (FSE:BAYG; BAY) said that single agent therapy with their BAY 43-9006 gave seven partial responses, five minor responses and 59 cases of stable disease in a Phase II trial in 137 advanced hepatocellular carcinoma (HCC) patients. Median overall survival was 9.2 months and median time to tumor progression was 4.2 months. ...